Form 4: Arcus CFO Sells Shares Under 10b5-1 Plan

Arcus Biosciences' Chief Financial Officer, Robert C. Goeltz II, sold 6,552 shares of common stock at $23.38 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Chief Financial Officer Robert C. Goeltz II of Arcus Biosciences, Inc. sold 6,552 shares of common stock.
• The transaction occurred on December 31, 2025, at a price of $23.38 per share.
• The sale was executed under a Rule 10b5-1 trading plan, which allows insiders to sell shares at a predetermined time or price.
• Following this transaction, Goeltz II beneficially owns 67,924 shares of Arcus Biosciences common stock.

Sentiment

Score: 5

Explanation: A neutral score. The sale is a routine insider transaction under a 10b5-1 plan, which typically has minimal immediate market impact unless the volume is exceptionally large or it's the first of many such sales, neither of which is indicated here.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than an immediate reaction to new, non-public information.

Negatives

• An insider sale, even if pre-planned, reduces management's direct equity stake, which can sometimes be perceived neutrally to slightly negatively by the market.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, which solely reports a past insider transaction.

Industry Context

Insider transactions, particularly sales under Rule 10b5-1 plans, are common across all industries. This type of transaction is generally viewed as routine and less indicative of management's immediate sentiment compared to an unplanned sale, as it is pre-scheduled to avoid accusations of trading on material non-public information. This specific transaction does not provide unique insights into broader industry trends for biotechnology companies like Arcus Biosciences.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a standard practice for executives to manage personal finances while complying with insider trading regulations.
• The volume of shares sold by the CFO represents a small fraction of the company's total outstanding shares and is typical for routine portfolio management by executives in similar-sized biotech firms, such as those seen at Gilead Sciences or Bristol Myers Squibb, where executives frequently use 10b5-1 plans for diversification or liquidity.

Stakeholder Impact

• Shareholders: The sale slightly reduces the CFO's direct ownership, which could be interpreted as a minor signal, though its impact is mitigated by the pre-arranged 10b5-1 plan, suggesting it's not based on new, adverse information.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

This Form 4 reports a routine insider sale by the CFO under a pre-arranged 10b5-1 trading plan. Such transactions are typically for personal financial management and do not inherently signal a change in the company's fundamental outlook or performance. Therefore, this filing provides no new information to warrant a change in investment recommendation based solely on this event. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Arcus Biosciences, RCUS, Insider Trading, Form 4, Stock Sale, CFO, Robert C. Goeltz II, 10b5-1 Plan, Equity Transaction